Literature DB >> 22057714

Dose dependence of intratumoral perivascular distribution of monoclonal antibodies.

John J Rhoden1, Karl Dane Wittrup.   

Abstract

Intravenously delivered antibodies have been previously found to distribute in a perivascular fashion in a variety of tumor types and despite targeting a range of different antigens. Properties of both the antibody and the targeted antigen, such as the administered dose, binding affinity, and antigen metabolic half-life, are predicted to influence the observed perivascular distribution. Here, the effect of antibody dose on the perivascular distribution is determined using an unbiased image analysis approach to quantify the microscopic distribution of the antibody around thousands of blood vessels per tumor. This method allows the quantitative determination of the localization of blood vessels, extravasated antibody, and tumor antigen following the administration of antibody doses covering two orders of magnitude in the dose range commonly utilized in preclinical studies. A mathematical model of antibody extravasation, diffusion, binding, and endocytosis in a Krogh cylinder geometry with parameters directly measured or taken from the literature is quantitatively consistent with the experimentally determined profiles. A previously reported scaling analysis is employed to extend these results to any tumor model in which the antigen density and turnover rate are known, allowing facile quantitative prediction of the minimum antibody dose required for complete tumor saturation.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057714      PMCID: PMC3971539          DOI: 10.1002/jps.22801

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  22 in total

1.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Microvascular permeability of normal and neoplastic tissues.

Authors:  L E Gerlowski; R K Jain
Journal:  Microvasc Res       Date:  1986-05       Impact factor: 3.514

Review 3.  Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.

Authors:  Robert A Beckman; Louis M Weiner; Hugh M Davis
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

Review 4.  Drug penetration in solid tumours.

Authors:  Andrew I Minchinton; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

5.  Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Authors:  Jennifer H E Baker; Kirstin E Lindquist; Lynsey A Huxham; Alastair H Kyle; Jonathan T Sy; Andrew I Minchinton
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 7.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

8.  Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Authors:  Margaret E Ackerman; David Pawlowski; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

9.  Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Authors:  Greg M Thurber; Stefan C Zajic; K Dane Wittrup
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

10.  Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.

Authors:  Ethaar El Emir; Uzma Qureshi; Jason L J Dearling; Geoffrey M Boxer; Innes Clatworthy; Amos A Folarin; Mathew P Robson; Sylvia Nagl; Moritz A Konerding; R Barbara Pedley
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more
  20 in total

1.  Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors.

Authors:  Sumit Bhatnagar; Emily Deschenes; Jianshan Liao; Cornelius Cilliers; Greg M Thurber
Journal:  J Pharm Sci       Date:  2014-07-21       Impact factor: 3.534

2.  Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors.

Authors:  Bruna Menezes; Jennifer J Linderman; Greg M Thurber
Journal:  Drug Metab Dispos       Date:  2021-10-14       Impact factor: 3.922

Review 3.  Key metrics to expanding the pipeline of successful antibody-drug conjugates.

Authors:  Ian Nessler; Bruna Menezes; Greg M Thurber
Journal:  Trends Pharmacol Sci       Date:  2021-08-26       Impact factor: 17.638

4.  Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.

Authors:  Eshita Khera; Shujun Dong; Haolong Huang; Laureen de Bever; Floris L van Delft; Greg M Thurber
Journal:  Mol Cancer Ther       Date:  2021-12-15       Impact factor: 6.009

5.  Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.

Authors:  Cornelius Cilliers; Bruna Menezes; Ian Nessler; Jennifer Linderman; Greg M Thurber
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

6.  Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.

Authors:  Cornelius Cilliers; Hans Guo; Jianshan Liao; Nikolas Christodolu; Greg M Thurber
Journal:  AAPS J       Date:  2016-06-10       Impact factor: 4.009

7.  A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.

Authors:  Jackson K Burton; Dean Bottino; Timothy W Secomb
Journal:  AAPS J       Date:  2019-12-11       Impact factor: 4.009

8.  Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers.

Authors:  Guolan Lu; Shayan Fakurnejad; Brock A Martin; Nynke S van den Berg; Stan van Keulen; Naoki Nishio; Ashley J Zhu; Stefania U Chirita; Quan Zhou; Rebecca W Gao; Christina S Kong; Nancy Fischbein; Mrudula Penta; Alexander D Colevas; Eben L Rosenthal
Journal:  Clin Cancer Res       Date:  2020-01-24       Impact factor: 13.801

9.  Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy.

Authors:  Brandon M Bordeau; Yujie Yang; Joseph P Balthasar
Journal:  Cancer Res       Date:  2021-03-16       Impact factor: 12.701

10.  Quantity and accessibility for specific targeting of receptors in tumours.

Authors:  Sajid Hussain; Maria Rodriguez-Fernandez; Gary B Braun; Francis J Doyle; Erkki Ruoslahti
Journal:  Sci Rep       Date:  2014-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.